Awakn Life Sciences Corp. (AWKNF)
USD 0.07
(0.0%)
USD 0.07
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 87.37 Thousand CAD | -99.13% |
| 2023 | 10.08 Million CAD | 2.39% |
| 2022 | 9.84 Million CAD | 573.6% |
| 2021 | 1.46 Million CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 FY | 3.99 Million CAD | -60.38% |
| 2024 Q4 | 859.45 Thousand CAD | 23.21% |
| 2024 Q3 | 697.56 Thousand CAD | -52.99% |
| 2024 Q2 | 1.48 Million CAD | -35.21% |
| 2024 Q1 | 2.29 Million CAD | -14.1% |
| 2023 FY | 10.08 Million CAD | 2.39% |
| 2023 Q3 | 2.16 Million CAD | -13.29% |
| 2023 Q4 | 2.66 Million CAD | 23.32% |
| 2023 Q2 | 2.49 Million CAD | -9.67% |
| 2023 Q1 | 2.76 Million CAD | -32.13% |
| 2022 Q3 | 2.86 Million CAD | 65.67% |
| 2022 Q2 | 1.72 Million CAD | 45.94% |
| 2022 Q1 | 1.18 Million CAD | 47.59% |
| 2022 FY | 9.84 Million CAD | 573.6% |
| 2022 Q4 | 4.06 Million CAD | 41.93% |
| 2021 FY | 1.46 Million CAD | 0.0% |
| 2021 Q4 | 803.17 Thousand CAD | 437.92% |
| 2021 Q2 | 509.6 Thousand CAD | 0.0% |
| 2021 Q3 | 149.31 Thousand CAD | -70.7% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 99.899% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 98.223% |
| SQZ Biotechnologies Company | 85.61 Million USD | 99.898% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 99.704% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 99.765% |
| Mesoblast Limited | 5.9 Million USD | 98.52% |
| Propanc Biopharma, Inc. | 1.5 Million USD | 94.182% |
| Genus plc | 147.7 Million USD | 99.941% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 99.005% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 93.487% |
| Marizyme, Inc. | 19.23 Million USD | 99.546% |
| ContraFect Corporation | 56.88 Million USD | 99.846% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 98.952% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 98.018% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | 94.091% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 97.004% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 96.869% |
| MultiCell Technologies, Inc. | 567.42 USD | -15298.294% |
| Accustem Sciences Inc. | 3.74 Million USD | 97.668% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 99.898% |
| EV Biologics, Inc. | 531.96 Thousand USD | 83.575% |
| Q BioMed Inc. | 3.43 Million USD | 97.458% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 99.646% |
| Neon Bloom, Inc. | 389.56 Thousand USD | 77.572% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 96.675% |
| Biomind Labs Inc. | 994.18 Thousand USD | 91.212% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 225.49 Million USD | 99.961% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 98.699% |
| Skye Bioscience, Inc. | 13.54 Million USD | 99.355% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | 95.735% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 449.492% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 98.267% |
| IMV Inc. | 37.7 Million USD | 99.768% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 99.454% |
| Curative Biotechnology, Inc. | 1.83 Million USD | 95.239% |
| GB Sciences, Inc. | 1.42 Million USD | 93.849% |
| Alpha Cognition Inc. | 9.7 Million USD | 99.1% |
| HST Global, Inc. | 140.9 Thousand USD | 37.992% |
| CSL Limited | 3.44 Billion USD | 99.997% |
| Halberd Corporation | 74.84 Thousand USD | -16.743% |
| Enzolytics Inc. | 2.17 Million USD | 95.991% |
| Resverlogix Corp. | 12.71 Million USD | 99.313% |
| Affymax, Inc. | 39.38 Million USD | 99.778% |
| SYBLEU INC | 160.87 Thousand USD | 45.689% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 97.607% |
| argenx SE | 1.53 Billion USD | 99.994% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 99.848% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | 91.631% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | 94.468% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 97.434% |
| AVAX Technologies, Inc. | 7.31 Million USD | 98.805% |
| Zenith Capital Corp. | 8.94 Million USD | 99.023% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.989% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -401.538% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 96.441% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | 49.056% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 99.912% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | 95.035% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 1.97 Million USD | 95.569% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | 95.314% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 99.196% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | 95.451% |
| BioStem Technologies, Inc. | 22.97 Million USD | 99.62% |
| ONE Bio Corp. | 6.44 Million USD | 98.644% |
| Reve Technologies, Inc. | 181.48 Thousand USD | 51.857% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | 93.457% |
| Wesana Health Holdings Inc. | 1.12 Million USD | 92.233% |
| Agentix Corp. | 1.37 Million USD | 93.631% |
| LadRx Corporation | 3.81 Million USD | 97.708% |
| Cell Source, Inc. | 4.32 Million USD | 97.98% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | 78.971% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 90.539% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 90.539% |
| NovAccess Global Inc. | 2.46 Million USD | 96.458% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 96.367% |
| Itoco Inc. | 919.14 Thousand USD | 90.494% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 97.939% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | 92.192% |
| Kadimastem Ltd | 2.41 Million USD | 96.375% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | 66.617% |
| CytoDyn Inc. | 18.05 Million USD | 99.516% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -247.145% |
| Mobile Lads Corp. | 554.54 Thousand USD | 84.244% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | 60.299% |
| Qrons Inc. | 643.67 Thousand USD | 86.426% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | 93.846% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | 96.082% |
| Rebus Holdings, Inc. | 664 Thousand USD | 86.841% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | 95.19% |
| International Stem Cell Corporation | 5.27 Million USD | 98.342% |
| Bioxytran, Inc. | 3.82 Million USD | 97.713% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -65.976% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -329.499% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 99.759% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | 94.6% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | 88.126% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 97.191% |
| Neutra Corp. | 243.82 Thousand USD | 64.165% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 99.499% |
| PureTech Health plc | 144.59 Million USD | 99.94% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 99.574% |
| IXICO plc | 4.7 Million USD | 98.144% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 99.007% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 99.926% |
| CSL Limited | 3.89 Billion USD | 99.998% |
| Cellectis S.A. | 97.32 Million USD | 99.91% |